Gaziva drug will be available for the treatment of patients chronic lymphocytic leukemia
Abstract
Новый препарат компании «Рош» Газива® (обину- тузумаб) для терапии пациентов с хроническим лим- фоцитарным лейкозом (ХЛЛ), которые не лечились ранее, станет доступен на российском рынке с сентя- бря 2015 г
References
1. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions NEJM 2014;370:1101–10. DOI:10.1056/NEJMoa1313984.
2. Lamanna N. et al. Chronic Lymphocytic Leukemia and Hairy-Cell Leukemia. Cancer Management [Available at: http://www.cancernetwork.com/cancer-management/chronic-lymphocytic-leukemia-and-hairycell-leukemia
3. Ferlay J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 2013; 49(6):1374–403. DOI: 10.1016/j.ejca.2012.12.027
4. GLOBOCAN Europe (2012) Estimate cancer incidence, all ages: both sexes [Available at: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute
5. GLOBOCAN Europe (2012) Estimate cancer mortality, all ages: both sexes [Available at: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=1&window=1&sort=0&submit=%C2%A0Execute
6. Goede V. et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015:1–3. DOI:10.1038/leu.2015.14.
Review
For citations:
Gaziva drug will be available for the treatment of patients chronic lymphocytic leukemia. Oncohematology. 2015;10(3):92-93. (In Russ.)
Views:
9370
Email this article 